CFO
MRNA icon

Callan Family Office’s Moderna MRNA Stock Holding History

Callan Family Office’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
+4,529
New +$234K 0.01% 981

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Callan Family Office's MRNA Position: Q2 2026 in Review

Callan Family Office opened a new position in Moderna (MRNA) in Q2 2026: 4,529 shares worth $317K. The stake represents 0.01% of the portfolio and ranks #981 among its holdings.

777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Callan Family Office held 4,529 shares of Moderna worth $317K as of Q2 2026.
  • Moderna was a new Callan Family Office position in Q2 2026.
  • Moderna made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #981 holding.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.